Journal article

The Effects of Female Sex, Viral Genotype, and IL28B Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection

Jason Grebely, Kimberly Page, Rachel Sacks-Davis, Maarten Schim van der Loeff, Thomas M Rice, Julie Bruneau, Meghan D Morris, Behzad Hajarizadeh, Janaki Amin, Andrea L Cox, Arthur Y Kim, Barbara H McGovern, Janke Schinkel, Jacob George, Naglaa H Shoukry, Georg M Lauer, Lisa Maher, Andrew R Lloyd, Margaret Hellard, Gregory J Dore Show all

HEPATOLOGY | WILEY | Published : 2014


UNLABELLED: Although 20%-40% of persons with acute hepatitis C virus (HCV) infection demonstrate spontaneous clearance, the time course and factors associated with clearance remain poorly understood. We investigated the time to spontaneous clearance and predictors among participants with acute HCV using Cox proportional hazards analyses. Data for this analysis were drawn from an international collaboration of nine prospective cohorts evaluating outcomes after acute HCV infection. Among 632 participants with acute HCV, 35% were female, 82% were Caucasian, 49% had interleukin-28 (IL28)B CC genotype (rs12979860), 96% had injected drugs ever, 47% were infected with HCV genotype 1, and 7% had hum..

View full abstract

University of Melbourne Researchers


Awarded by National Institute on Drug Abuse (NIDA)

Awarded by NIH

Awarded by Alberta Innovates



Funding Acknowledgements

The InC<SUP>3</SUP> Study is supported by the National Institute on Drug Abuse (NIDA; award no.: R01DA031056). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDA or the National Institutes of Health (NIH). The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this article do not necessarily represent the position of the Australian Government. J. Gr. is supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship. J. B. and N. H. S. are supported by Fonds de la Recherche du Quebec-Sante Research Career Awards. B. H. is supported by an Australian Postgraduate Ph. D. Award. G. D. and A. L. are supported by NHMRC Practitioner Research Fellowships. M. H. and L. M. were supported by NHMRC Senior Research Fellowships and M. H. additionally by a VicHealth Senior Research Fellowship. R. S. D. was supported by an NHMRC postgraduate scholarship and a Centre for Research Excellence into Injecting Drug Use postgraduate top-up scholarship. Other research support includes NIH U19 AI088791 (to A. C.), NIH U19 AI066345 (to A.Y.K., G. M. L., and B. H. M.), U19 AI082630 (the National Institute of Allergy and Infectious Diseases; to G. M. L.), R01 DA033541 (NIDA; to A.Y.K.), MOP-103138 and MOP-210232 (the Canadian Institutes of Health Research; to J. B. and N. H. S.), and the Netherlands National Institute for Public Health and the Environment (to M. Svd. L. and M. P.). J. Ge. is supported by the Sydney Medical Foundation and grants from the NHMRC.